Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis

Published:2024-09-11 Issue: Volume: Page:
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

de Fries Jensen Lasse^ORCID,Antavalis Vasileios,Odgaard-Jensen Jan,Rossi Annachiara,Pietropoli Alberto,Højby Michael

Funder

Novo Nordisk

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02966-y.pdf

Reference39 articles.

1. Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab. 2016;30:737–47. https://doi.org/10.1016/j.beem.2016.11.002.

2. Dattani M, Preece M. Growth hormone deficiency and related disorders: insights into causation, diagnosis, and treatment. Lancet. 2004;363:1977–87. https://doi.org/10.1016/j.beem.2016.11.002.

3. Loftus J, Heatley R, Walsh C, Dimitri P. Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature. J Pediatr Endocrinol Metab. 2010;23:535–51. https://doi.org/10.1515/jpem.2010.092.

4. Ben-Ari T, Chodick G, Shalev V, Goldstein D, Gomez R, Landau Z. Real-world treatment patterns and outcomes of growth hormone treatment among children in Israel over the past decade (2004–2015). Front Pediatr. 2021;9: 711979. https://doi.org/10.3389/fped.2021.711979.

5. Miller BS. What do we do now that the long-acting growth hormone is here? Front Endocrinol (Lausanne). 2022;13: 980979. https://doi.org/10.3389/fendo.2022.980979.